India, June 19 -- AstraZeneca Plc. (AZN.L, AZN) said that Japan approved Breztri Aerosphere, formerly PT010, as a triple-combination therapy to relieve symptoms of chronic obstructive pulmonary disease or COPD.
It is the first approval by the Japanese Ministry of Health, Labour and Welfare for a triple-combination therapy in a pressurised metered-dose inhaler, which uses the Aerosphere delivery technology.
COPD is a progressive disease which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness.
Breztri Aerosphere is under priority review in China, with a regulatory decision expected in the second half of 2019. The medicine is also under regulatory review in the US and EU with decisions anticipat...